Phenylephrine + CPM Syrup

Phenylephrine + CPM Syrup belongs to the Syrups category within the Cough & Cold, Anti-Histamines, and Respiratory therapeutic segments. Unlike three-active combination cold syrups that include an antitussive, this two-molecule formula is clinically focused on the nasal and allergic symptom cluster — the right choice for prescribers when dry cough is not present but nasal blockage and rhinorrhea are the dominant complaints.

The two-molecule clinical rationale is straightforward and well-established in Indian prescribing practice:

• Phenylephrine HCl 5mg per 5ml — a selective alpha-1 adrenergic nasal decongestant that causes vasoconstriction in the nasal submucosal vessels, reducing mucosal edema and restoring nasal patency within 15–30 minutes of oral dosing.
• Chlorpheniramine Maleate 2mg per 5ml — a first-generation H1 antihistamine that blocks histamine-driven rhinorrhea, sneezing, and watery eye symptoms, with mild sedation that can assist nighttime comfort during acute cold illness.

For pharmaceutical marketing companies, this is a clean, high-frequency SKU with year-round demand driven by allergic rhinitis and seasonal cold presentations — positioning well as a standalone branded cold-allergy syrup or as part of a broader respiratory portfolio alongside three-active DMR-containing products. Saar Biotech manufactures it from our facility in Baddi with validated two-API quality control and the full range of 60ml and 100ml packaging options the category demands.

At Saar Biotech, we manufacture Phenylephrine + CPM Syrup using a controlled oral syrup manufacturing process that ensures precise two-API assay accuracy, consistent flavour quality, and packaging flexibility for both economy and premium brand formats.

• Two-API Assay Precision: Simultaneous HPLC quantification of Phenylephrine HCl and Chlorpheniramine Maleate on every batch ensures both actives meet 100% label claim accuracy throughout the shelf life. Even small assay deviations in a two-active product create a proportionally larger impact on the clinical outcome than in multi-active combinations — our validated analytical protocols eliminate this risk.
• Orange Flavour Masking: Chlorpheniramine Maleate carries a characteristic mild bitterness that is particularly detectable in a two-active base where there are fewer competing flavour notes. Our flavour system is specifically calibrated for this combination to ensure complete bitterness masking with a clean, commercially standard orange profile that maintains palatability from the first dose to the last in a 100ml bottle.
• pH-Stabilised Vehicle: The liquid base is formulated within a validated pH range that maintains both Phenylephrine and Chlorpheniramine chemically stable across the 24-month shelf life under Indian tropical storage conditions. pH drift is one of the primary degradation drivers for both molecules and is rigorously controlled at every production stage.
• Versatile Pack Format Support: From 15ml dropper packs for physician-directed pediatric use to 60ml and 100ml consumer retail formats — with metallic labels, drip-off cartons, orange flavour designation, and tricolour measuring caps — Saar Biotech’s packaging range covers every price tier and channel requirement in this category.

Phenylephrine + CPM Syrup is manufactured and supplied by Saar Biotech for the following clinically established indications in cold, allergic rhinitis, and upper respiratory symptom management:

• Nasal Congestion & Blocked Nose: The primary indication. Phenylephrine’s alpha-1 vasoconstriction reduces mucosal engorgement in the nasal passages, improving airflow and relieving the blocked-nose discomfort that dominates most cold presentations.
• Runny Nose & Rhinorrhea: Chlorpheniramine Maleate suppresses the histamine-driven glandular hypersecretion responsible for profuse nasal discharge — controlling both viral cold-associated rhinorrhea and allergen-triggered nasal drip.
• Sneezing & Watery Eyes: The H1 antihistamine component addresses sensory nerve stimulation in the nasal mucosa and conjunctiva, reducing sneezing episodes and allergic lacrimation that accompany rhinitis presentations.
• Allergic Rhinitis Symptom Management: Seasonal and perennial allergic rhinitis patients benefit from the combination’s dual decongestion and antihistamine coverage, making it a useful adjunct to steroid nasal sprays in moderate rhinitis management.

Schedule H — Requires valid medical prescription. Patients should be advised about potential sedation from CPM and to avoid driving or alcohol during treatment.

Dual-Component Clinical Action

Phenylephrine Hydrochloride acts as a direct-acting sympathomimetic amine with selective affinity for alpha-1 adrenergic receptors on the vascular smooth muscle of the nasal submucosa. Stimulation of these receptors causes rapid vasoconstriction, reducing the local blood flow responsible for mucosal engorgement and the edematous tissue swelling that narrows nasal passages. Unlike non-selective sympathomimetics, Phenylephrine’s alpha-1 selectivity at standard therapeutic doses minimizes the beta-adrenergic cardiovascular effects (tachycardia, palpitations) that can occur with older decongestants, giving it a more favorable cardiac safety profile for routine cold prescribing.

Chlorpheniramine Maleate is a classical alkylamine first-generation antihistamine. It acts as a competitive, reversible antagonist at the histamine H1 receptor, preventing histamine from binding to and activating these receptors on respiratory mucosa, capillary endothelium, and sensory nerve endings. By blocking H1 activation, it prevents the histamine-driven increase in vascular permeability that produces rhinorrhea, inhibits the glandular secretion that generates nasal discharge, and suppresses the sensory nerve stimulation that triggers sneezing. Its CNS penetration produces predictable mild-to-moderate sedation — a clinical effect that requires patient counseling but can be beneficial for nighttime symptom control.

Manufacturing Integrity

• Two-API Chemical Compatibility: Phenylephrine and Chlorpheniramine Maleate must remain chemically inert to each other in the aqueous syrup base throughout the shelf life. Saar Biotech’s formulation team selects a pH, preservative, and excipient system validated for compatibility of both molecules simultaneously — preventing any degradation of either active through cross-interaction or unfavorable vehicle chemistry.
• Flavour System Stability: The orange flavour must maintain its sensory quality over 24 months under tropical storage conditions. Our flavour selection and preservative system are validated to resist flavour fade and off-note development — ensuring batch-to-batch sensory consistency that protects brand reputation through distribution and retail shelf life.

• Rapid Nasal Relief Onset: Oral Phenylephrine achieves meaningful nasal decongestant effect within 15–30 minutes of administration, with a duration of approximately 4 hours. This fast onset creates a clear, patient-perceptible clinical outcome within the first dose — critical for building first-prescription loyalty and repeat use in the cold-allergy segment.
• Clean Two-Active Portfolio Position: Unlike three-active DMR + Phenylephrine + CPM formulas, the two-active Phenylephrine + CPM product does not suppress cough. This makes it the correct clinical choice — and the correct marketing message — when a patient’s presentation is dominated by nasal and allergic symptoms without significant cough. For B2B partners, this creates a distinct prescriber positioning from their cough-syrup SKUs.
• Year-Round Market Applicability: Allergic rhinitis is a perennial condition in India driven by dust mite, mold, and environmental allergen exposure year-round. Unlike cough-cold products with seasonal demand peaks, Phenylephrine + CPM Syrup maintains a more consistent prescription frequency throughout the year — reducing the inventory risk associated with highly seasonal formulations.
• Pack Versatility: The 15ml dropper serves pediatric prescriptions and sampling, the 60ml covers short course treatment, and the 100ml covers adult prescriptions for patients with chronic rhinitis. This tiering allows B2B partners to address multiple channels and price points from one formulation.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Phenylephrine + CPM Syrup from our oral liquid manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Dedicated oral liquid filling lines for syrups in 15ml, 60ml, and 100ml presentations with automated filling, capping, labeling, and carton packing.
• Capacity: Scalable from brand-entry batch sizes to high-volume seasonal supply; 100×100ml and 160×60ml shipper configurations available.
• Quality Lab: In-house GLP-certified laboratory with validated HPLC assay for both Phenylephrine HCl and Chlorpheniramine Maleate, plus pH, specific gravity, MLT, and fill volume checks.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 15ml, 60ml, and 100ml amber PET bottles; sticker label, metallic label, silver leafing, gold leafing, drip-off UV carton, embossed brand carton, measuring cap, tricolour ring measuring cap, citra-logo golden cap, WHO-GMP golden cap, logo-printed PP cap, with-carton or without-carton options.
• MOQ: Starting at 5,000–10,000 units per SKU.

1. Warehouse Conditions: Store sealed bottles below 30°C in a cool, dry place. High ambient temperatures accelerate flavour degradation and can affect the stability of both active molecules — particularly Phenylephrine, which is susceptible to oxidative degradation at elevated temperatures.
2. Light Protection: Keep bottles away from direct sunlight. Amber PET bottles and outer cartons provide adequate photo-protection during transit and pharmacy shelf display.
3. Measuring Cap Use: A calibrated measuring cap ensures accurate 5ml dose delivery. Household spoons are unreliable and can result in sub- or supra-therapeutic dosing, particularly important when CPM’s sedative effect must be managed predictably.
4. Post-Opening: Tightly close the cap after each use to prevent microbial ingress and flavour evaporation. The bottle should be used within its labeled shelf life period.

Every commercial batch of Phenylephrine + CPM Syrup is quarantined until it passes a comprehensive analytical release protocol:

• Two-API HPLC Assay: Simultaneous quantification of Phenylephrine HCl 5mg and Chlorpheniramine Maleate 2mg per 5ml via validated High-Performance Liquid Chromatography against Indian Pharmacopoeia (IP) specifications — confirming 100% label claim accuracy for both actives before batch release.
• pH & Specific Gravity: Monitored to confirm syrup base stability and correct viscosity characteristics for the expected pour and dose measurement behavior.
• Appearance, Colour & Flavour: Batch-to-batch sensory consistency verified — particularly important for the orange flavour profile where colour and taste are part of the brand’s identity at pharmacy level.
• Microbial Limit Testing (MLT): IP-compliant testing confirming absence of specified pathogens and acceptable total microbial count for oral liquid products.
• Fill Volume & Pack Inspection: Automated fill-volume checks, cap torque, label placement, and measuring-cap inclusion verified before dispatch.
• Certificate of Analysis (COA): Issued with every B2B consignment for partner records, distributor verification, and regulatory documentation.

• CNS Sedation (CPM): Chlorpheniramine produces drowsiness and somnolence. Patients must be warned against driving, operating machinery, or consuming alcohol during treatment.
• Cardiovascular Caution (Phenylephrine): May raise blood pressure at standard oral doses. Use with caution in patients with hypertension, coronary artery disease, or hyperthyroidism.
• Critical Drug Interaction: Phenylephrine is contraindicated with MAO inhibitors and tricyclic antidepressants. A 14-day washout period after MAO inhibitor discontinuation is required before use.
• Contraindications: Known hypersensitivity to any component; narrow-angle glaucoma; urinary retention; uncontrolled severe hypertension.
• Healthcare professionals should review complete prescribing information before recommending in elderly patients, pregnant or lactating women, and those on antihypertensive or CNS-active medication.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Phenylephrine + CPM Syrup, please use the B2B enquiry form below.